FUNCTION: SwissProt: Q8IWL2 # In presence of calcium ions, it binds to surfactant phospholipids and contributes to lower the surface tension at the air-liquid interface in the alveoli of the mammalian lung and is essential for normal respiration.
SIZE: 248 amino acids; 26242 Da
SUBUNIT: Oligomeric complex of 6 set of homotrimers.
SUBCELLULAR LOCATION: Secreted, extracellular space.
DISEASE: SwissProt: Q8IWL2 # Genetic variations in SFTPA1 are associated with respiratory distress syndrome in premature infants (RDS) [MIM:267450]; also known as RDS in prematurity. RDS in the newborn is the main cause of mortality and morbidity in premature infants. RDS is characterized by deficient gas exchange that is caused by diffuse atelectasis and high-permeability lung edema that results in fibrin-rich alveolar deposits called ′hyaline membranes′. The risk of bronchopulmonary dysplasia increases with the severity of RDS.
SIMILARITY: SwissProt: Q8IWL2 ## Contains 1 C-type lectin domain. & Contains 1 collagen-like domain.
MISCELLANEOUS: Pulmonary surfactant consists of 90% lipid and 10% protein. There are 4 surfactant-associated proteins: 2 collagenous, carbohydrate-binding glycoproteins (SP-A and SP-D) and 2 small hydrophobic proteins (SP-B and SP-C).

Bovine SP-A

Immunoblot: 1:1,000-1:5,000

ELISA: 1:1,000-1:30,000

Optimal dilutions must be determined by the end user.

Reacts strongly with bovine and sheep SP-A.

Rabbit serum. Liquid. Contains no preservative.

Maintain at -20°C in undiluted aliquots for up to twelve months. Avoid repeated freeze/thaw cycles.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.